Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Erector Spinae Plane Blocks for Pain Control After Total Laparoscopic Hysterectomy

12. november 2026 oppdatert av: Hande Gurbuz

Effects of Erector Spinae Plane Block and Deep Erector Spinae Plane Block on Postoperative Pain Management in Total Laparoscopic Hysterectomy

This study will compare two nerve block techniques for pain relief after total laparoscopic hysterectomy, a minimally invasive operation to remove the uterus. Both techniques involve injecting a local anesthetic near muscles of the lower back, but the injections are given at different depths.

Women aged 18 to 65 years who are scheduled for this surgery will be randomly assigned to one of three groups: erector spinae plane block, deep erector spinae plane block, or no nerve block. The nerve blocks will be performed on both sides of the lower back after surgery. All participants will receive standard pain medication.

The main aim is to compare pain scores one hour after surgery. The study will also assess pain during the first 24 hours, opioid pain medication use, the time until additional pain relief is needed, nausea and vomiting, time to hospital discharge, patient satisfaction, and quality of recovery.

Studieoversikt

Detaljert beskrivelse

This single-center, prospective, randomized controlled study will compare ultrasound-guided bilateral erector spinae plane block and deep erector spinae plane block with a control group receiving no block in women undergoing total laparoscopic hysterectomy under general anesthesia.

Participants will be allocated to three groups using computer-generated randomization. Blocks will be performed postoperatively in the recovery unit at the L1 vertebral level. In the erector spinae plane block group, the injection will be administered between the erector spinae muscle and the transverse process. In the deep erector spinae plane block group, the injection will be administered deep to the transverse process, in the plane between the erector spinae and psoas muscles. Both block groups will receive 20 mL of 0.25% bupivacaine on each side. The control group will receive no block.

All groups will receive standardized general anesthesia and perioperative multimodal analgesia. Intravenous meperidine at 0.25 mg/kg will be administered as rescue analgesia when the numerical rating scale pain score exceeds 3.

An anesthesiologist blinded to group allocation will assess pain at rest and during movement. Baseline pain scores (0 minutes) will be recorded before block administration. Subsequent pain assessments in the block groups will be timed from completion of bilateral block administration. In the control group, an equivalent reference time will be established in the postoperative recovery unit, and the same assessment schedule will be followed. Postoperative assessments will include pain scores, opioid consumption, rescue analgesic requirements, nausea and vomiting, discharge time, patient satisfaction, and quality of recovery using the Quality of Recovery-15 questionnaire.

Studietype

Intervensjonell

Registrering (Antatt)

87

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Hande Gurbuz, Prof, MD, PhD
  • Telefonnummer: +90 533 651 56 50
  • E-post: handegrbz@gmail.com

Studiesteder

    • Bursa
      • Bursa, Bursa, Tyrkia (Türkiye), 16110
        • University of Health Sciences, Bursa City Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Female patients aged 18 to 65 years.
  • Scheduled for elective total laparoscopic hysterectomy.
  • American Society of Anesthesiologists (ASA) physical status I, II, or III.
  • Provision of written informed consent.

Exclusion Criteria:

  • ASA physical status IV or higher.
  • Inability to cooperate with pain assessment because of cognitive impairment, a psychiatric condition, or inability to understand Turkish.
  • Known allergy to local anesthetics or opioids.
  • Body mass index greater than 35 kg/m².
  • Infection at the planned injection site.
  • Neurological deficits.
  • Alcohol or drug dependence.
  • Known or suspected coagulopathy.
  • Severe hepatic, cardiac, or renal disease.
  • Emergency surgery or repeat surgery.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Erector Spinae Plane Block

Participants will receive an ultrasound-guided bilateral erector spinae plane block at the L1 vertebral level in the postoperative recovery unit. On each side, 20 mL of 0.25% bupivacaine will be injected into the plane between the erector spinae muscle and the transverse process. Participants will also receive standardized perioperative multimodal analgesia and rescue analgesia as needed.

Ultrasound-guided bilateral erector spinae plane block performed at the L1 vertebral level in the postoperative recovery unit. Following confirmation of needle placement and negative aspiration, 20 mL of 0.25% bupivacaine without adjuvants will be injected between the erector spinae muscle and the transverse process on each side.

Eksperimentell: Deep Erector Spinae Plane Block

Participants will receive an ultrasound-guided bilateral deep erector spinae plane block at the L1 vertebral level in the postoperative recovery unit. On each side, 20 mL of 0.25% bupivacaine will be injected into the plane between the erector spinae and psoas muscles, deep to the transverse process. Participants will also receive standardized perioperative multimodal analgesia and rescue analgesia as needed.

Ultrasound-guided bilateral deep erector spinae plane block performed at the L1 vertebral level in the postoperative recovery unit. Following confirmation of needle placement and negative aspiration, 20 mL of 0.25% bupivacaine without adjuvants will be injected into the plane between the erector spinae and psoas muscles, deep to the transverse process, on each side.

Ingen inngripen: Control Group

Participants will receive no nerve block. They will receive the same standardized perioperative multimodal analgesia as the two block groups, with rescue analgesia administered as needed.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pain Intensity at Rest at 1 Hour After Block Administration
Tidsramme: At 1 hour after block administration or the equivalent reference time in the control group

Pain intensity at rest will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable). Higher scores indicate greater pain intensity. Assessment will occur 1 hour after completion of bilateral block administration or the equivalent reference time in the control group.

At 1 hour after block administration or the equivalent reference time in the control group

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pain Intensity During Movement at 1 Hour After Block Administration
Tidsramme: At 1 hour after Block Administration

Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable). Higher scores indicate greater pain intensity. At 1 hour after block administration or the equivalent reference time in the control group

At 1 hour after Block Administration
Pain Intensity at Rest Before and After Block Administration
Tidsramme: At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery

Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable), at baseline (before block administration) and at 15 and 30 minutes and 6, 18, and 24 hours after block administration, with corresponding assessments in the control group. Higher scores indicate greater pain intensity. Scores will be compared between groups at each assessment time point.

At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery
Pain Intensity During Movement Before and After Block Administration
Tidsramme: At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery

Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable), at baseline (before block administration) and at 15 and 30 minutes and 6, 18, and 24 hours after block administration, with corresponding assessments in the control group. Higher scores indicate greater pain intensity. Scores will be compared between groups at each assessment time point.

At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery
Cumulative Rescue Opioid Consumption During the First 24 Hours After Surgery
Tidsramme: During the first 24 hours after surgery

The total dose of intravenous meperidine administered as rescue analgesia during the first 24 hours after surgery will be recorded in milligrams. Rescue analgesia will be administered at a dose of 0.25 mg/kg when the numerical rating scale (NRS) pain score exceeds 3. Higher consumption indicates a greater requirement for rescue opioid analgesia.

During the first 24 hours after surgery
Time to First Rescue Analgesia
Tidsramme: From the end of surgery to the first administration of rescue analgesia, up to 24 hours

The time from the end of surgery to the first administration of rescue analgesia will be recorded in minutes. Intravenous meperidine at 0.25 mg/kg will be administered when the numerical rating scale (NRS) pain score exceeds 3. Participants who do not receive rescue analgesia during the first 24 hours will be censored at 24 hours.

From the end of surgery to the first administration of rescue analgesia, up to 24 hours
Postoperative Nausea and Vomiting Severity
Tidsramme: During the first 24 hours after surgery

Postoperative nausea and vomiting will be assessed using a five-point scale: 0 = none, 1 = mild nausea, 2 = moderate nausea, 3 = one episode of vomiting, and 4 = more than one episode of vomiting. Higher scores indicate greater severity.

During the first 24 hours after surgery
Quality of Recovery at 24 Hours After Surgery
Tidsramme: Preoperatively and at 24 hours after surgery

Quality of recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The questionnaire contains 15 items, with a total score ranging from 0 to 150. Higher scores indicate better quality of recovery. The questionnaire will be administered preoperatively and at 24 hours after surgery.

Preoperatively and at 24 hours after surgery

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Hande Gurbuz, Prof, MD, PhD, University of Health Sciences, Bursa School of Medicine, Bursa City Hospital

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. desember 2027

Studiet fullført (Antatt)

1. desember 2027

Datoer for studieregistrering

Først innsendt

12. november 2026

Først innsendt som oppfylte QC-kriteriene

12. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

There is currently no plan to share individual participant data with other researchers.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere